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Background: The objective of this study was to evaluate the effect of bone marrow mesenchymal stem cells
(BMSCs) on the apoptosis of granulosa cells (GCs) in rats.
BMSCs and GCs were isolated from rats. GCs were separated into one of the following three groups: an untreated
control group (control), a cisplatin (5 mg/L) treatment group (cisplatin), and group co-cultured with BMSCs and
treated with cisplatin (BMSC). GC apoptosis was analyzed by annexin V staining and real-time PCR analysis for
apoptosis-related genes. The effect of BMSCs was also determined in 9 to 10 month-old perimenopausal rats that
were separated into the following groups: saline control, BMSC transplantation (1–2 × 106 cells), and estrogen
treatment (0.158 mg/kg/d) groups. A young group consisting of 3 to 4 month-old rats that were treated with saline
was also evaluated as a control. After 1 and 3 months, GC apoptosis was evaluated by TUNEL analysis.
Results: Cisplatin increased GC apoptosis from 0.59% to 13.04% in the control and cisplatin treatment groups,
respectively, which was significantly reduced upon co-culture with BMSCs to 4.84%. Cisplatin treatment increased
p21 and bax and decreased c-myc mRNA expression, which was reversed upon co-culture with BMSCs. As
compared to young rats, increased apoptosis was observed in the perimenopausal rats (P < 0.001). After 3 months,
the apoptosis rate in the BMSC group was significantly lower than that of the control group (P = 0.007).
Conclusions: BMSC therapy may protect against GC apoptosis induced by cisplatin and perimenopause. Further
studies are necessary to evaluate therapeutic efficacy of BMSCs.
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Perimenopause or the permanent end of menstruation
and fertility is characterized by reduced estrogen levels
and disorder of the hypothalamus-pituitary-ovary/ad-
renal axis. Therefore, estrogen replacement therapy is
commonly prescribed to increase the quality of life for
individuals in perimenopause. However, significant risks
have been associated with estrogen replacement therapy,
including increased risk of breast cancer, endometrial
cancer, and cardiovascular events [1-3]. Thus, better
treatments without the associated risks are required.* Correspondence: tanjm156@yahoo.com.cn
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reproduction in any medium, provided the orGranulosa cells (GCs) are responsible for estrogen syn-
thesis within the ovary and subsequent follicular atresia,
and their numbers decrease in perimenopause [4]. Ther-
apies that prevent their apoptosis may represent a novel
treatment modality. Previous studies have shown that
mesenchymal stem cells (MSCs), including those derived
from bone marrow (BMSCs), are capable of repairing a
variety of injured tissues [5,6] due to their potential to
differentiate into osteoblasts, chondrocytes, adipocytes,
cardiocytes, and neural cells [7]. In rats with chemo-
therapy-induced ovarian damage, BMSC transplantation
improved ovarian structure and function [8]. However,
little is known about the therapeutic effects of BMSCs
on GC apoptosis associated with perimenopause.
The objective of this study was to evaluate the ef-
fect of BMSCs on the apoptosis of ovarian GCs in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lated from rats and characterized using microscopy, im-
munocytochemistry, and flow cytometry. In vitro GC
apoptosis was induced by cisplatin in GCs co-cultured
with and without BMSCs. In addition, GC apoptosis was
analyzed in the perimenopausal rats treated with BMSCs
and estrogen using TUNEL assays and compared to un-
treated controls and young rats. BMSC therapy may re-
present a novel treatment for perimenopause that may
have less deleterious effects than estrogen replacement
therapy.Results
Characterization of cultured BMSCs and GCs
Isolated BMSCs in culture were characterized by micros-
copy and flow cytometry analyses. Freshly isolated and
cultured BMSCs were adherent, with most displaying
polygonal morphology (Figure 1A). By the third passage,
BMSC morphology resembled fibroblasts with few con-
taminant cells (Figure 1B). Most of the cultured BMSCs
expressed CD29 (99.1% positive) and CD90 (98.2% po-
sitive) but were negative for markers of the hematopoie-
tic lineage, including CD34 (1.01% positive) and CD45
(1.32% positive) (Figure 1E-H), which is consistent with
previous studies [9,10].
To determine the extent to which induction resulted
in BMSC differentiation toward osteoblasts versus adi-
pocytes lineages, cells were examined after Von Kossa
staining. As shown in Figure 1C (black cells) and 1D
(red cells), isolated BMSCs were capable of differentia-
ting into both osteoblasts and adipocytes. Furthermore,
the basal secretion of large amounts of angiogenic and
antiapoptotic factors from BMSCs cells after three days in
culture was observed and included 1674.22 ± 182.80 pg/mL
vascular endothelial growth factor (VEGF), 22255.75 ±
3473.66 pg/mL hepatocyte growth factor (HGF), and
0.9237 ± 0.13 ng/mL insulin-like growth factor-1 (IGF-1).
Isolated GCs were also characterized by microscopy
and immunocytochemistry. Cultured GCs were adherent
and displayed polygonal morphology (Figure 2A). Cul-
tured GCs also expressed intracellular follicle stimula-
ting hormone receptor (FSHR), confirming their identity
as GCs (Figure 2B).Effects of BMSCs on GC apoptosis in vitro
To determine whether BMSCs could protect GCs against
cisplatin-induced apoptosis, GCs cultured in the absence
or presence of BMSCs were treated with cisplatin. As
shown in Figure 3, cisplatin increased apoptosis from
0.59% to 13.04% in the control and cisplatin groups,
respectively (Figure 3A and 3B). However, co-culture
with BMSCs significantly reduced GC apoptosis to 4.84%
(Figure 3C).Real-time PCR analysis was next undertaken to deter-
mine the effect of BMSC co-culture on the mRNA ex-
pression of apoptosis-related genes (Figure 4, N = 6 for
each group). Although no significant changes in survivin
and bcl-2 mRNA expression were observed among the
three treatment groups, differences in p21 (P = 0.033),
c-myc (P = 0.029), and bax (P < 0.001) mRNA expression
were detected. Co-culture of GCs with BMSCs signifi-
cantly decreased p21 mRNA expression (2.944 ± 1.322
vs. 1.034 ± 1.492, P = 0.046). Cisplatin treatment decrea-
sed c-myc mRNA expression as compared to the control
group (1.253 ± 0.789 vs. 0.314 ± 0.177, P = 0.028), and
this effect was ameliorated with BMSC co-culture. Fur-
thermore, a significant increase in bax mRNA expression
was observed with cisplatin treatment as compared to
the control group (2.934 ± 0.955 vs. 1.019 ± 0.211, re-
spectively; P < 0.001); however, it significantly decreased
upon co-culture with BMSCs (0.476 ± 0.167, P < 0.001;
Figure 4).
Effects of BMSCs in an in vivo model of perimenopause
To determine if BMSC transplantation influences the
GC apoptosis associated with perimenopause, an in vivo
model was established in middle-aged rats (Figure 5,
N = 5 for each group). Both treatment (P < 0.0001) and
time (P = 0.0008) had significant effect on the apoptosis
rates. However, the interaction of time and treatment on
the apoptosis rates was not significant (P = 0.638). As
compared young rats, increased apoptosis was observed
in the middle-aged rats after one month (1.53 ± 1.44%
vs. 9.90 ± 3.23%, P < 0.001; Figure 5). After intervention
with BMSC therapy or estrogen for 1 month, the apop-
tosis rate was lower than the control group although a
significant difference was not observed. After 3 months,
the apoptosis rate in the BMSC group (8.29 ± 3.35%,
P = 0.007) was significantly lower than that of the con-
trol group (14.60 ± 3.51%). No difference in estrogen
treatment was observed.
Discussion
In the present study, co-culture with BMSCs signifi-
cantly reduced cisplatin-mediated GC apoptosis and
cisplatin-induced changes in p21, bax, and c-myc mRNA
expression. In an in vivo model of perimenopause, the GC
apoptosis rate was significantly lower in rats receiving
BMSC therapy as compared to the control group after
three months.
BMSCs account for 1–10 per 100,000 nucleated cells
within bone marrow [11]. Although their isolation is re-
latively simple and they amplify in abundance in vitro,
an ideal marker of BMSCs has yet to be identified. In
this study, BMSCs expressed CD29 and CD90, but not
CD34 and CD45, which is in agreement with Stagg et al.
[9]. Characterization of their differentiation potential
Figure 1 BMSC morphology and surface marker expression. BMSC morphology and differentiation was assessed by microscopy of BMSCs (A)
in the first passage, (B) third passage, (C) after Von Kossa staining for visualization of osteoblasts after induction, (D) and after Oil red staining for
adipocytes after induction (200×). (E) CD90, CD45, CD34, and Cd29 surface market expression was determined using flow cytometry.
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and adipocytes in vitro. In addition, BMSCs can differen-
tiate into chondrocytes, tenocytes, and neural cells [7].
Cisplatin induces DNA crosslinking, which triggers
apoptosis. In the present study co-culture with BMSCsreduced GC apoptosis induced by cisplatin, which is in
agreement with a previous study [8]. Also, co-culture of
GCs with BMSCs downregulated the mRNA expression
of Bax and p21 and upregulated c-myc mRNA expres-
sion in GCs. Bcl-2 and Bax are both apoptosis regulating
Figure 2 GC morphology and FSHR expression. (A) Primary GC morphology was assessed by microscopy. (B) Intracellular expression of FSHR
by GCs was observed by immunocytochemistry (400×).
Guo et al. BMC Cell Biology 2013, 14:18 Page 4 of 9
http://www.biomedcentral.com/1471-2121/14/18proteins that effect the mitochondria [12,13]; Bcl-2 com-
petes with Bax for interaction with adenine nucleotide
translocator (ANT) on the mitochondrial membrane, pre-
venting apoptosis [14]. In addition, p21 overexpression
may promote apoptosis [15-17]; it regulates the cell cycle
through p53-dependent and independent pathways [18].
Finally, c-myc promotes cell cycle progression from the
G0/G1 phase to the S phase [14]; its downregulation has
been associated with Bax oligomerization and subsequent
activation of caspase-9 and caspase-3, resulting in apop-
tosis [19]. Because BMSCs and GCs were separated by a
semipermeable membrane, protection by BMSCs was elic-
ited through secreted paracrine factors. However, further
studies are necessary to identify the precise paracrine me-
diator(s) responsible for this protective effect.
Perimenopause is defined as occurring 12 months
after the last menstrual period. At present, there are
four animal models of perimenopause, including an
ovarectomized animal model, a model that physically
or pharmacologically disrupts of ovarian function, aFigure 3 Effects of BMSCs on GC apoptosis in vitro. The apoptosis rate4-vinylcyclohexene diepoxide (VCD) follicle depletion
model, and a natural aging animal model. The natural
aging animal model was selected for this study as it
most closely models the pathological changes associa-
ted with perimenopause.
BMSC transplantation reduced GC apoptosis, which is
in accordance with two previous studies describing the
restorative effects of MSCs after their transplantation
into ovaries [8,20]. However, the mechanism by which
the BMSCs influenced GC apoptosis remains unclear as
they were introduced via injection into vena caudalis.
For example, the transplanted BMSCs may have reached
the site of injury within the ovary and replaced damaged
tissue through integration into the ovarian tissue and
differentiation into the required cell type. Alternatively,
the BMSCs may have induced tissue repair and pre-
vented apoptosis by secreting paracrine mediators, in-
cluding glial cell-derived neurotrophic factor (GDNF),
brain-derived neurotrophic factor (BDNF), tumor nec-
rosis factor (TNF), basic fibroblast growth factor (bFGF)of GCs in the control (A), cisplatin (B) and BMSC co-culture (C) groups.
Figure 4 Effects of BMSCs on apoptosis-related genes in GCs. Relative gene expression levels were determined using real-time PCR among
the control (lanes 1), cisplatin (lanes 2), and BMSC co-culture (lanes 3) groups. (A) Representative images for each gene analyzed were shown.
(B) Relative gene expressions levels by using real-time PCR. * indicates a significant difference from the control group; P < 0.05, † indicates a
significant difference from the cisplatin group; P < 0.05. N = 6 for each group.
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ter mechanism is supported by the in vitro study that
showed reduced GC apoptosis with BMSC co-culture, in
which the cells were not in direct contact. Furthermore,
analysis of cell culture supernatant revealed that BMSCs
secreted IGF-1, HGF, and VEGF-A. VEGF promotes the
formation of capillary networks, ensuring nutrition for
GCs and oocytes [25]. In the ovary, IGF-1 regulates
DNA replication of theca cells and GCs; it also regulates
aromatase activity, secretion of inhibin, and generation
of corpus luteum stimulating hormone receptor [26].IGF-1 also prevents cell cycle progression from G0/G1
to S via PI3K/Akt signaling and inhibits Fas receptor-
mediated apoptosis [27]. Finally, GCs express the HGF
receptor, c-met [28]. Uzumcu et al. [29] reported that
the level of HGF was inversely proportional to GC apop-
tosis, and HGF can reduce GC apoptosis in vivo and
vitro. Further studies will be undertaken to elucidate the
mechanism by which BMSCs influence GC apoptosis.
The present study has some limitations. For example,
basic characterization of the perimenopausal rats was
using vaginal smears to detect estrous cycle, estrous cycle
Figure 5 Effects of BMSCs in an in vivo model of perimenopause. GC apoptosis was assessed by TUNEL staining. (A) Representative images
of ovarian tissues obtained from the young, BMSC, control, and estrogen groups one (top panels) and three (bottom panels) months after the
intervention are shown (200×). (B) GC apoptosis rates among the control, BMSC, estrogen, and young groups after 1 and 3 months intervention.
Values are presented as mean ± SD. * indicates a significant difference from control; P < 0.05 (Two-way ANOVA: treatment effect, P < 0.0001; time
effect, P = 0.0008). N = 5 for each group.
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menopause, estrogen therapy, or BMSC therapy on ovar-
ian hormone levels in the serum were not determined. In
addition, the in vivo study lacked a BMSC-only treatment
group. Furthermore, the protein levels of c-myc, p21, sur-
vivin, Bcl-2, and Bax were not assessed to corroborate the
data obtained using RT-PCR. Finally, the mechanism by
which BMSCs influence GC apoptosis (i.e., integration
and/or paracrine mediators) remains unclear and will be
the subject of further studies.Conclusion
BMSCs decrease the GC apoptosis in vitro and vivo.
Further studies will evaluate the therapeutic efficacy of
BMSC therapy for perimenopausal symptoms as well as
the basis for these effects.Methods
Experimental animals
Immature male (60–80 g), young female (3–4 months),
and perimenopausal female (9–10 months) Sprague–
Dawley rats were obtained from the Animal Center at
Shanghai. All rats were kept under controlled temperature
(30 ± 2°C) and light (14 h light, 10 h dark) conditions with
rat chow and water ad libitum. All experiments were
approved by the institutional animal committee of the
Fuzhou General Hospital.Isolation and identification of BMSCs
The femurs and tibiae were removed from immature
male Sprague–Dawley rats. The bone marrow plugs were
flushed with phosphate-buffered saline (PBS), layered
over a Percoll solution (density 1.083), and separated
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perature. Mononuclear cells at the interface were recov-
ered and washed twice with PBS. The cells were cultured
with complete medium, consisting of DMEM/F12 (1:1)
medium supplemented with 10% fetal bovine serum (FBS;
Hyclone, Logan, UT), 100 U/mL penicillin, and 100 U/mL
streptomycin at 37°C and 5% CO2. At confluence, the cells
were harvested for passage with 0.25% trypsin containing
0.02% EDTA. All experiments were performed using cells
from the third to fifth passage.
BMSC surface expression of CD29, CD34, CD45, and
CD90 was analyzed by flow cytometry. Briefly, cells were
incubated with the R-phycoerythrin (PE)-labeled anti-
bodies (BD Biosciences, San Jose, California, USA) and
their corresponding isotype controls: PE-CD34 (no dilu-
tion), PE-CD29 (1:16 dilution), PE-CD45 (1:8 dilution),
and PE-CD90 (1:8 dilution). After a 30-min incubation
in the dark, the cells were isolated by centrifugation
(800 g for 5 min) after which the supernatant was remo-
ved. After the cells were washed three times with 2 mL
PBS, the cell suspensions were filtered with 200 μm
mesh filters to make single cell suspensions. 1× 106Cells
were next analyzed for surface marker expression by
flow cytometry (Beckman Coulter, Inc., Brea, CA, USA).
Samples in which the primary antibody was omitted were
used as the gate for the forward scatter (FSC) versus side
scatter (SSC).
BMSCs were seeded in 6-well plates at a density of
1 × 105 cells/well. After 24 h, the supernatant in one
of the plates was replaced with control DMEM-HG
medium supplemented with 10% FBS, 10-6 M dexame-
thasone, 0.5 mM 3-methyl-1-methyl xanthine, 10 μg/mL
insulin, and 0.2 mM indomethacin. In the remaining
plates, the supernatant was replaced with induction me-
dium comprised of DMEM-HG medium supplemen-
ted with 10% FBS, 10-7 M dexamethasone, 10 mM
beta-glycerophosphate, and 50 mg/mL vitamin C. The
medium was replaced every three days. The cells cul-
tured in control medium were stained with Oil red
after two weeks; the cells cultured in induction me-
dium were identified by Von Kossa staining after three
weeks.
To evaluate the secretion of growth factors, including
vascular endothelial growth factor (VEGF), hepatocyte
growth factor (HGF), and insulin-like growth factor-1
(IGF-1), by cultured BMSCs, cells were seeded in 6-well
plates at a density of 1 × 106 cells/well. After 24 h, the
supernatant was replaced with serum-free medium con-
sisting of DMEM/F12 (1:1) medium, 100 U/mL peni-
cillin, and 100 U/mL streptomycin. After three days, the
supernatant was collected, and cytokine concentrations
were determined using enzyme linked immunosorbent
analysis (ELISA) using kits purchased from Uscn (Wu
Han, Hubei, China).Isolation and identification of GCs
Immature female rats (3–4 weeks) were injected once
subcutaneously with 60 IU of pregnant mare serum go-
nadotropin (Animal Drugs Factory, Huangzhou, Zhejiang,
China) to induce the development of multiple antral fol-
licles. After 48 h, the rats were sacrificed, and the ovaries
removed. The GCs were isolated by needle puncture
under an inverted microscope. After obtaining single cell
suspensions, they were washed twice with PBS and cul-
tured with complete medium, including DMEM/F12 (1:1)
medium supplemented with 10% FBS, 100 U/mL penicil-
lin, and 100 U/mL streptomycin at 37°C and 5% CO2. Cell
of the third passage were seeded on microscope slides for
immunocytochemistry analysis to confirm their identity.
Briefly, single GC suspensions (1 × 105 cells/mL) were fi-
xed with 4% paraformaldehyde and washed three times
with PBS (5 min/wash) and then incubated with 0.5% Tri-
ton X-100 for 20 min at room temperature. After washing
three times with PBS (5 min/wash), cells were incubated
with 3% H2O2 for 5 min at room temperature to eli-
minate endogenous catalase activity. Nonspecific bind-
ing was blocked by incubating the cells will normal goat
serum diluted in PBS (1:50) for 20 min at room tempe-
rature. Next, samples were incubated with FSHR primary
polyclonal antibodies (1:200; Santa Cruz Biotechnology,
Santa Cruz, CA) diluted in PBS in a humidified chamber
at 4°C overnight. Controls consisted of samples incubated
in PBS alone. After washing three times with PBS (5 min/
wash), secondary goat anti-rabbit lgG antibodies were
added for 60 min at 37°C. After three washes with PBS
(5 min/wash), samples were incubated with a horseradish
peroxidase-labeled streptomycin solution for 30 min at
37°C prior to color development with the 3,3' Diamino-
benzidine (DAB) chromogen. After the reaction was
stopped by washing the samples with tap water, the sam-
ples were counterstained with hematoxylin for 20 s.
Subsequently, the samples were washed, dehydrated,
mounted with Permount (Fischer, Fair Lawn, NJ, USA),
and analyzed using a Leica TCS-2 microscope (Leica
Microsystems Ltd., North Point, Hong Kong, China)
equipped with a D1X digital camera (Leica Microsystems
Ltd., North Point, Hong Kong, China).
Effect of BMSCs on GC apoptosis in vitro
Prior to in vitro experiments, 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays
(Sigma-Alderich, St Lois, MO, USA) were used to identify
the optimal concentrations of cisplatin as well as optimal
treatment time without inducing toxicity. GCs (1 × 104
cells/well) in logarithmic growth were seeded onto a
96-well plate and incubated with various concentra-
tions of cisplatin (0, 1.875, 3.25, 7.5, 15, and 30 mg/L).
After 24, 48, 72, 96, or 120 h, 20 μL of MTT solution
(5 mg/L) was added to each well for 4 h after which 150
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each well was determined at wavelength 490 nm using a
Stat Fax 2100 Microplate Reader (Awareness Technology,
INC., Palm City, FL, USA).
Cultured GCs were separated into three groups: an
untreated control group (control), a cisplatin (5 mg/L)
treatment group (cisplatin), and group co-cultured with
BMSCs and treated with 5 mg/L cisplatin (BMSC). GCs
were seeded onto 6-well plates at a density of 5 × 105
cells/well. BMSCs were seeded on 6-well Millicell cell
culture inserts (Millipore, Billerica, MA, USA) at a den-
sity of 2.5 × 105 cells/well. After 24 h, the supernatant
was removed. In the control group, the medium was
changed to 3 mL serum-free medium (DMEM/F12 me-
dium containing 100 U/mL penicillin and 100 U/mL
streptomycin). In the cisplatin group, cells were incu-
bated with 3 mL serum-free medium with cisplatin
(5 mg/L). In the BMSC co-culture group, cells were co-
cultured with BMSCs and incubated with 3 mL serum-
free medium with cisplatin (5 mg/L). After 72 h, the
GCs were harvested and analyzed for apoptosis using
an annexin V/PI apoptosis detection kit (MultiSciences
Biotech, China) according to manufacturer’s protocols and
flow cytometry (Beckman Coulter Epics XL Flow Cytome-
ter; GMI, Inc.; Ramsey, Minnesota, USA).Real time PCR analysis
GCs from each of the three treatment groups were also
harvested to extract RNA. Bcl-2, bax, survivin, c-myc,
p21, and GAPDH (housekeeping gene) mRNA expres-
sion was examined by real-time PCR using the following
primers: and GAPDH mRNA expression was serving as
control. The primers sequences are listed as follows:
GAPDH (180 bp) sense, 5’-AAGGT CATCCCAGAG
CTGAA-3’ and antisense, 5’-CTCAGTGTAGCCCAGG
ATGC-3’; c-myc (166 bp)sense,5’-TCTCTTCTTCCTCG
GACTCG-3’and antisense, 5’-GGTTGCCTCTTTT CCA
CAGA-3’; p21 (169 bp) sense, 5’-GAGTGCCTTGAC
GATACAGC-3’ and antisense, 5’-CATGTACTGGTC
CCTCATTGC-3’; survivin (180 bp) sense, 5’-GGAGCA
TAGG AAGCACTCCCCTG-3’ and antisense, 5’-CTCC
GGGTCTCCTCGAACTCTT-3’; Bcl-2 (173 bp) sense,
5’-AGTACCTGAACCGGCATCTG-3’ and antisense, 5’-
CAGGTATG CACCCAGAGTGA-3’ and Bax (174 bp)
sense, 5’-CTGCAGAGGATGATTGCTGA-3’ and anti-
sense, 5’-GATCAGCTCGGGCACTTTAG-3’. PCR amp-
lification conditions consisted of an initial denaturation
step of 2 min at 93°C followed by 40 cycles of 95°C for
15 sec and 60°C for 1 min using an ABI 7500 PCR ma-
chine (Applied Biosystems; Foster City, CA, USA). The
CT values from real time PCR results were analyzed by
the 2-△△CT method. The PCR products were validated by
running in 120 V × 20 min electrophoresis conditions.Effects of BMSCs on GC apoptosis in vivo
Rats reach sexual maturity at 6 to 8 weeks and pe-
rimenopause at 10 to 15 months. Female rats (9–10
months) were randomly divided into the following three
groups (n = 15 per group): control group, BMSC group,
and estrogen group. In addition, 15 adult female rats
(3–4 months) were included as the young group. Prior
to initiation of the experiment, vaginal smears of the fe-
male rats were obtained at 8:30 am every morning to
confirm the perimenopausal status of the older rats ac-
cording to the estrous cycle. Upon confirmation, BMSCs
(1–2 × 106 cells in 2 mL) were injected via vena caudalis
of rats in the BMSC group; the control and young
groups received a 2 mL saline injection. This treatment
was repeated after one week. Rats in the estrogen group
received 0.158 mg/kg/d nilestriol (Shang Hai New Hua
Lian Pharmaceutical CO.LTD, China) for 8 consecutive
days by gavage administration. Five rats from each group
were randomly sacrificed one and three months after the
second transplantation, and their ovaries were removed.
The left ovary was fixed in formaldehyde and sectioned
for analysis of GC apoptosis using a TUNEL apoptosis
assay kit (Roche, Branford, CT). Tissue sections from
each animal were examined by microscopy, and at least
100 GCs per field were counted in five randomly se-
lected fields. The GC apoptosis rate was calculated as
the number of apoptotic GCs divided by the total num-
ber of GCs. Cells were counted independently by two in-
dividuals who were blinded to the treatment group. The
apoptotic index was defined as the average GC apoptosis
rate from counted five randomly selected fields.
Statistical analysis
Quantitative data are presented as mean ± SD. Differen-
ces in gene expression among the three groups (control,
cisplatin, and BMSC groups) were detected by one-way
analysis of variance (ANOVA) with Tukey’s range test.
The GC apoptosis rates were analyzed by two-way
ANOVA to evaluate treatment effect (control, BMSC,
estrogen) and age as well as time effect (1 month vs.
3 months) along with their interaction. The statistical
analyses were performed with SAS software version 9.2
(SAS Institute Inc., Cary, NC). A two-tailed P-value < 0.05
indicated statistical significance.
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